Precision Optics Corporation announced a public offering of 2,777,777 shares at $3.60 each, aiming for working capital and corporate purposes.
Quiver AI Summary
Precision Optics Corporation, Inc. announced the pricing of its public offering of 2,777,777 shares of common stock at $3.60 per share, with the offering oversubscribed and including participation from company management. The offering, led by Lucid Capital Markets, will provide net proceeds for working capital and general corporate purposes. A 45-day option for the underwriter to purchase an additional 416,667 shares is also included. The offering is expected to close around March 30, 2026, and is registered under a previously filed shelf registration statement. Precision Optics specializes in advanced optical instruments for the medical and defense/aerospace sectors.
Potential Positives
- The successful pricing of the upsized public offering with 2,777,777 shares indicates strong investor interest, suggesting confidence in the company's future prospects.
- Participation from key executives, including the President and CEO, shows insider confidence and alignment with investor interests.
- The raised capital will be utilized for working capital and general corporate purposes, which may strengthen the company's operational capabilities and support growth initiatives.
- The offering's lead manager, Lucid Capital Markets, is reputable, indicating the potential for a well-managed fundraising process and positive market perception.
Potential Negatives
- The pricing of the public offering at $3.60 per share may indicate a lack of confidence in the company's market value, especially if this price is perceived as low by investors.
- The need to conduct an underwritten public offering could suggest financial instability or a necessity to raise capital due to operational challenges.
- Potential dilution of existing shareholders' equity due to the issuance of 2,777,777 new shares in the offering, which could negatively impact share value and investor sentiment.
FAQ
What is Precision Optics Corporation's recent announcement?
Precision Optics Corporation announced the pricing of an underwritten public offering of 2,777,777 shares of common stock at $3.60 each.
Who led the recent public offering of Precision Optics?
The offering was led by a mix of existing and new fundamental institutional investors, including company executives.
When is the expected closing date for the offering?
The offering is expected to close on or about March 30, 2026, subject to customary closing conditions.
What will the proceeds from the offering be used for?
The net proceeds will be used for working capital and general corporate purposes.
How can investors obtain the prospectus for the offering?
Investors can access the prospectus on the SEC's website and contact Lucid Capital Markets for additional copies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$POCI Revenue
$POCI had revenues of $7.4M in Q2 2026. This is an increase of 62.76% from the same period in the prior year.
You can track POCI financials on Quiver Quantitative's POCI stock page.
$POCI Hedge Fund Activity
We have seen 11 institutional investors add shares of $POCI stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG removed 41,491 shares (-98.3%) from their portfolio in Q4 2025, for an estimated $173,639
- MESIROW FINANCIAL INVESTMENT MANAGEMENT, INC. removed 23,364 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $97,778
- DRW SECURITIES, LLC added 22,528 shares (+inf%) to their portfolio in Q4 2025, for an estimated $94,279
- NEEDHAM INVESTMENT MANAGEMENT LLC added 20,000 shares (+2.9%) to their portfolio in Q4 2025, for an estimated $83,699
- NORTHERN TRUST CORP added 16,599 shares (+inf%) to their portfolio in Q4 2025, for an estimated $69,466
- JUNIPER INVESTMENT COMPANY, LLC removed 15,502 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $64,875
- MORGAN STANLEY added 14,000 shares (+18.0%) to their portfolio in Q4 2025, for an estimated $58,589
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
GARDNER, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the pricing of its previously announced underwritten public offering of 2,777,777 shares of its common stock at a public offering price of $3.60 per share, before deducting underwriting discounts and commissions and offering expenses.
The oversubscribed offering was led by a mix of existing and new fundamental institutional investors and included participation from directors, officers and executive management of the company including Dr. Joseph N. Forkey, the company’s President, Chief Executive Officer and member of its Board of Directors, Wayne Coll, the company’s Chief Financial Officer, and Joseph Traut, the company’s Chief Operating Officer, who each purchased shares of common stock in this offering at the public offering price and on the same terms as the other purchasers in this offering.
Lucid Capital Markets is acting as the sole book-running manager for the offering.
All of the shares of common stock to be sold in the offering will be sold by the Company. In addition, the Company has granted the underwriter a 45-day option to purchase up to an additional 416,667 shares of its common stock at the public offering price less the underwriting discounts and commissions. The offering is expected to close on or about March 30, 2026, subject to customary closing conditions.
The Company intends to use net proceeds from this offering for working capital and general corporate purposes. The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-280047) filed with the Securities and Exchange Commission (“SEC”) on June 7, 2024, as amended on June 11, 2024, and declared effective by the SEC on June 14, 2024.
A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement will be filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained by contacting Lucid Capital Markets, LLC, 570 Lexington Avenue, 40th Floor, New York, NY 10022.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Precision Optics Corporation
Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics, 3D imaging and digital imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release include, without limitation, the Company’s ability to complete the offering and the use of proceeds of the offering. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the demand for the Company’s products, global supply chains and economic activity in general and other risks and uncertainties identified in the Company’s filings with the SEC. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
Company Contact:
PRECISION OPTICS CORPORATION
22 East Broadway
Gardner, Massachusetts 01440-3338
Telephone: 978-630-1800
Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Telephone: 602-889-9700
[email protected]